Breast Carcinoma Cell Targeted Therapy by Novel Vitamin D Analog.
Abstract
Recently we have shown that 1-alpha (OH)D5, a novel vitamin D analog has both cell differentiating and growth inhibitory effects in selected human breast carcinoma cell lines. We observed enhanced expression of intracytoplasmic casein and lipid droplets, nm23 and ICAM-1 proteins following days in vitro treatment with 1-alpha (OH)D5. In the proposed study we further evaluated effect of this novel compounds on other biomarkers associated with breast cancer cell differentiation. We studied in vivo and in vitro effects of 1-alpha (OH)D5 on 4 different cell lines. 1-alpha (OH)D5 showed pronounced growth inhibitory effect in all ER+ breast carcinoma cells. It enhanced expression of alpha2 integrin, beta-1 integrin, and CK-8 proteins in breast cancer cells irrespective of their ER status. Changes in expression of later proteins was only observed in VDR+ cells. In vivo, 1-alpha (OR)D5 supplemented in diet inhibited growth of ZR-75-1 and UISO-BCA-4 cells. Our ultimate goal is to conjugate and link this vitamin D analog to Her-2/neu antibody in order to specifically target breast cancer cells in women. We selected ZR-75-1 cells (known to have overexpression of Her-2 receptor) for further in vivo work. In vivo growth of ZR-75-1 cells was significantly reduced by Her-2 antibody treatment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1998
- Accession Number
- ADA364678
Entities
People
- Rajeshwari R. Mehta
Organizations
- University of Illinois at Chicago